Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01750320 · ClinicalTrials.gov registry record · Phase 1
Koning Breast Computed Tomography Guided Biopsy
A Phase 1 study of Breast Cancer, sponsored by Koning Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT01750320: Completed Phase 1 study of Breast Cancer, sponsored by Koning Corporation.
NCT01750320 is a Phase 1 study of Breast Cancer that has completed, run by Koning Corporation. The registered enrollment target is 4 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01750320, a Phase 1 study of Breast Cancer, has completed, sponsored by Koning Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary aim of this study is to show that the accuracy of Koning Breast CT-guided biopsy is at least equivalent to that of stereotactic-guided biopsy.
Conditions Studied
Interventions
- DEVICE Koning Breast CT-guided Biopsy
Study Locations (1)
New York
- Elizabeth Wende Breast Care - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2012-08 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01750320
The ClinicalTrials.gov registry entry for NCT01750320 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Koning Corporation, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Koning Breast CT-guided Biopsy is the first listed.
NCT01750320 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01750320 about?
NCT01750320 is a clinical study titled "Koning Breast Computed Tomography Guided Biopsy". The primary aim of this study is to show that the accuracy of Koning Breast CT-guided biopsy is at least equivalent to that of stereotactic-guided biopsy.
What is the current status of trial NCT01750320?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2012-08. Estimated completion is 2015-12.
What conditions does trial NCT01750320 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT01750320?
The interventions under investigation include: Koning Breast CT-guided Biopsy (DEVICE).
Who is sponsoring clinical trial NCT01750320?
This trial is sponsored by Koning Corporation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01750320 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.